可溶性fms样酪氨酸激酶1与胎盘生长因子比值对双胎妊娠子痫前期的预测价值:系统综述与Meta分析
该系统综述与Meta分析检索PubMed、Embase和Cochrane数据库至2023年8月6日,纳入7项研究共442例双胎妊娠孕妇(115例子痫前期患者和327例无子痫前期对照),评估可溶性fms样酪氨酸激酶1与胎盘生长因子比值预测子痫前期的诊断准确性。汇总特异度0.89(95%CI 0.80-0.95)、敏感度0.84(95%CI 0.73-0.93),受试者工作特征曲线下面积0.92。
要点
- 汇总特异度0.89(95%CI 0.80-0.95),敏感度0.84(95%CI 0.73-0.93)。
- 汇总阳性似然比32.76(95%CI 12.82-83.74),阴性似然比0.03(95%CI 0.01-0.08)。
- 汇总诊断比值比35.72(95%CI 12.92-98.76),受试者工作特征曲线下面积0.92。
核心结论
- 这些汇总发现强调可溶性fms样酪氨酸激酶1与胎盘生长因子比值有潜力作为识别双胎妊娠女性中子痫前期的准确标志物。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase和Cochrane数据库从建库至2023年8月6日,无语言限制。
- 纳入前瞻性队列研究和观察性比较研究,共7项研究,包括442例双胎妊娠女性(115例子痫前期患者和327例无子痫前期对照)。
主要发现
- 汇总特异度为0.89(95%CI 0.80-0.95),敏感度为0.84(95%CI 0.73-0.93)。
- 汇总阳性似然比为32.76(95%CI 12.82-83.74),阴性似然比为0.03(95%CI 0.01-0.08)。
- 汇总诊断比值比为35.72(95%CI 12.92-98.76),受试者工作特征曲线下面积为0.92。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In recent years, the ratio of soluble fms-like tyrosine kinase 1 to placental growth factor for use in predicting preeclampsia has been explored extensively. Despite extensive research, available data on its effectiveness in predicting preeclampsia in twin pregnancies are limited and conflicting. This meta-analysis aimed to assess the diagnostic accuracy of the soluble fms-like tyrosine kinase 1 to placental growth factor ratio in distinguishing cases with preeclampsia in twin pregnancies from healthy controls. DATA SOURCES: Studies that evaluated the use of the soluble fms-like tyrosine kinase 1 to placental growth factor ratio in predicting preeclampsia were searched in PubMed, Embase, and Cochrane databases from inception to August 6, 2023, without language restriction. STUDY ELIGIBILITY CRITERIA: The following population, exposure, comparators, outcomes, and study designs were included: women with twin pregnancies; an increased soluble fms-like tyrosine kinase 1 to placental growth factor ratio with preeclampsia as the outcome; women without preeclampsia; a 2 × 2 diagnostic table, diagnostic accuracy data, and the incidence of preeclampsia; and prospective cohort studies and observational comparative studies, respectively. STUDY APPRAISAL AND SYNTHESIS METHODS: The quality of the included studies was evaluated. Key parameters, including the specificity, sensitivity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio, were calculated using the random- and fixed-effects models. In addition, the area under the receiver operating characteristic curve and the summary receiver operating characteristic curve were evaluated. RESULTS: A total of 7 studies were included, including 442 women with twin pregnancies (115 patients with preeclampsia and 327 controls without preeclampsia). The results highlighted the promising effectiveness of the soluble fms-like tyrosine kinase 1 to placental growth factor ratio in predicting preeclampsia in twin pregnancies with a pooled specificity of 0.89 (95% confidence interval, 0.80-0.95), a sensitivity of 0.84 (95% confidence interval, 0.73-0.93), a positive likelihood ratio of 32.76 (95% confidence interval, 12.82-83.74), and a negative likelihood ratio of 0.03 (95% confidence interval, 0.01-0.08). The combined diagnostic odds ratio was 35.72 (95% confidence interval, 12.92-98.76), and the area under the receiver operating characteristic curve was 0.92. CONCLUSION: These collective findings underscore the potential of the soluble fms-like tyrosine kinase 1 to placental growth factor ratio as an accurate marker for identifying preeclampsia among women with twin pregnancies.
引用
- Yang M, Bai Y, Li M, et al. Predictive value of the soluble fms-like tyrosine kinase 1 to placental growth factor ratio for preeclampsia in twin pregnancies: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2024. PMID: 38401234. doi:10.1016/j.ajogmf.2024.101290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。